We limit data available in the Overview Report for users who do not have Powerpack
Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Target Price Range
Recommendation Rating
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | ‡‡‡‡ | 1.42 | 0.98 | 0.40 | 0.36 | — | — | — |
Low Price
|
| — | — | — | — | — | ‡‡‡‡‡ | 12.11 | 4.71 | 5.20 | 3.07 | — | — | — |
High Price
|
| — | — | — | — | — | ‡‡‡‡‡ | 86 | 95 | 100 | 122 | — | — | — |
Employees
|
| — | — | — | — | — | ‡‡‡ | 0.00 | 0.00 | 0.25 | 0.44 | — | — | — |
Revenue/Emp
|
| — | — | — | — | — | — | — | — | 25.38 | 53.43 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue
|
| — | — | — | — | — | ‡‡‡ | 0.00% | — | 93.63% | 92.99% | — | — | — |
Gross Margin
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | (241.32) | (198.64) | (169.92) | (52.49) | — | — | — |
EBT
|
| — | — | — | — | ‡‡‡ | ‡‡‡ | 0.00% | 0.00% | (669.42%) | (98.25%) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
EBT Margin
|
| — | ‡‡‡ | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | (241.32) | (198.64) | (169.92) | (52.49) | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Net Income
|
| — | — | — | — | — | ‡‡‡‡‡ | (1.56) | 0.91 | 3.11 | 2.11 | — | — | — |
Depreciation
|
| — | — | — | — | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.21 | 0.31 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue/Sh
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | (2.23) | (1.81) | (1.43) | (0.30) | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Earnings/Sh
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | (2.03) | (1.58) | (1.44) | (0.34) | — | — | — |
Cash Flow/Sh
|
| — | — | — | — | ‡‡‡ | ‡‡‡‡‡ | (0.02) | (0.01) | 0.00 | 0.00 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Capex/Sh
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | (2.05) | (1.59) | (1.44) | (0.34) | — | — | — |
Free CF/Sh
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 3.29 | 1.62 | 0.57 | 1.40 | ‡‡‡‡ | — | — |
Book Value/Sh
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 108.27 | 109.53 | 118.56 | 172.21 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Shares
|
| — | — | — | — | — | — | — | — | 0.00 | 0.00 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
PE Ratio
|
| — | — | — | — | — | — | — | — | 0.00 | 7.96 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PS Ratio
|
| — | — | — | — | — | — | — | — | 0.77 | 1.76 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PB Ratio
|
| — | — | — | — | — | — | — | — | 0.00 | 3.77 | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ |
EV/Sales
|
| — | — | — | — | — | — | — | — | 0.09 | (3.45) | — | — | — |
EV/FCF
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | (219.99) | (173.16) | (170.49) | (58.13) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Op' Cash Flow
|
| — | — | — | — | — | ‡‡‡‡‡ | (1.70) | (0.61) | (0.14) | (0.15) | ‡‡‡‡‡ | — | — |
Capex
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | (221.69) | (173.78) | (170.63) | (58.29) | ‡‡‡‡‡ | — | — |
FCF
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 351.89 | 174.59 | 38.71 | 213.30 | — | — | — |
Working Cap'
|
| — | — | — | — | — | — | 3.72 | — | — | — | — | — | — |
Total Debt
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | (368.27) | (200.64) | (69.35) | (226.69) | — | — | — |
Net Debt
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 355.97 | 177.47 | 67.54 | 241.54 | — | — | — |
Sh' Equity
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | (48.11%) | (64.88%) | (94.75%) | (25.83%) | — | — | — |
ROA
|
| — | — | — | — | ‡‡‡ | ‡‡‡ | 0.00% | 0.00% | 0.00% | (233.82%) | — | — | — |
ROIC
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | (52.81%) | (74.48%) | (138.71%) | (33.96%) | — | — | — |
ROE
|
Analyst Commentary (Summary)
Invivyd, Inc. (IVVD) Latest News
1 Sep
Invivyd appoints chairman Marc W. Elia as CEO while approaching results from VYD2311 studies DECLARATION and LIBERTY. CEO appointment plus pending pivotal trial data create major potential shifts in operations and investor sentiment.
13 Aug
Invivyd reported a Q2 loss and missed revenue estimates. Q2 loss and revenue shortfall signals weaker financial performance likely pressuring near-term stock valuation.
Invivyd reports second quarter 2026 financial results and recent business highlights. Quarterly financial results and business updates typically influence near-term market performance and investor sentiment.
6 Jul
IVVD stock drops after PEMGARDA loses emergency authorization in 2027 as Invivyd shifts focus to full FDA approval. Loss of emergency authorization for lead product PEMGARDA creates major regulatory and revenue pressure on IVVD while full approval path introduces execution risk and timeline uncertainty.
Invivyd received twelve months’ advance notice of EUA termination for PEMGARDA® and updated next steps with the FDA. EUA termination notice for PEMGARDA directly threatens Invivyd's main product revenue stream and forces strategic pivot.
19 Jun
Invivyd doses first participants in Phase 3 trial for VYD2311. Phase 3 trial start for VYD2311 advances core clinical pipeline toward potential approval.
16 Jun
Invivyd completed enrollment in its Phase 3 LIBERTY trial evaluating VYD2311 antibody versus mRNA COVID-19 vaccine. Phase 3 enrollment completion advances VYD2311 toward potential approval and revenue generation.
9 Jun
Invivyd initiates dosing of first participants in Phase 3 COVID-19 trial. Phase 3 trial start advances clinical pipeline toward potential regulatory approval and revenue.
Invivyd doses first participants in Phase 3 trial of COVID-19 antibody VYD2311. Phase 3 trial start for VYD2311 advances Invivyd's lead candidate toward potential approval.
Invivyd dosed first participants in LIBERTY Phase 3 trial evaluating VYD2311 antibody safety and tolerability versus mRNA COVID vaccine plus safety and immunology of antibody and vaccine co-administration. Phase 3 start for VYD2311 advances Invivyd's COVID antibody pipeline with a key clinical milestone.
1 Jun
Invivyd completes enrollment in its upsized DECLARATION Phase 3 pivotal trial of VYD2311, an investigational monoclonal antibody for COVID-19 prevention. Phase 3 enrollment completion marks a major development milestone that advances VYD2311 toward potential approval and revenue generation.
15 May
Invivyd, Inc. held its Q1 2026 earnings call covering financial results and company outlook. Quarterly earnings releases typically produce moderate effects on near-term stock sentiment and operations.
14 May
Invivyd Inc (IVVD) Q1 2026 earnings call highlights strong revenue growth and strategic investments. Strong revenue growth and strategic investments indicate major positive shifts in financial performance and competitive positioning.
Invivyd, Inc. (IVVD) reported first quarter 2026 financial results and recent business highlights. Quarterly financial results and business highlights signal key performance metrics that can significantly sway investor sentiment and stock trajectory.
Invivyd, Inc. (IVVD) released Q1 earnings call highlights covering financial results, operational updates, and forward-looking guidance. Q1 earnings call highlights provide insights into financial performance and strategy with moderately noticeable effects on investor sentiment and trajectory.
Invivyd, Inc. (IVVD) reported a Q1 net loss and revenue below analyst estimates. Q1 loss and revenue miss indicate weaker-than-expected financial performance, moderately affecting investor sentiment and stock trajectory.
24 Apr
Invivyd (IVVD) announces favorable Phase 3 analysis results for VYD2311, a next-generation COVID-19 monoclonal antibody treatment. Favorable Phase 3 results for VYD2311 position Invivyd for potential FDA approval and new revenue in the COVID-19 market.
9 Apr
Invivyd announces progress in its REVOLUTION program and advances VMS063, a novel monoclonal antibody candidate positioned as potential first- and best-in-class for measles treatment and prevention. Advancing a potential first-in-class measles antibody expands Invivyd's infectious disease pipeline, enhancing long-term growth prospects and investor sentiment.
Invivyd updates VYD2311 REVOLUTION trials with modest study upsizing and unveils measles monoclonal antibody VMS-063. Trial upsizing and new measles mAb introduction moderately bolster pipeline innovation and competitive positioning.
5 Mar
Invivyd, Inc. (IVVD) released Q4 earnings call highlights, covering financial results, operational updates, and forward guidance. Q4 earnings highlights reveal key financial metrics and strategic outlook that significantly shape investor expectations and stock trajectory.
Invivyd Inc. (IVVD) reported strong revenue growth and strategic advancements in its Q4 2025 earnings call highlights. Strong revenue growth and strategic highlights signal major positive shifts in financial performance and market positioning.
Invivyd, Inc. (IVVD) released Q4 2025 earnings call summary detailing financial results, operational updates, and future outlook. Q4 earnings call summary discloses financial performance and guidance, significantly influencing IVVD's trajectory and investor sentiment.
Invivyd, Inc. (IVVD) reported fourth quarter and full-year 2025 financial results, recent business highlights, and updates on the DECLARATION clinical trial. Full-year financial results and DECLARATION clinical trial updates represent major disclosures on financial performance and pipeline advancement.
Invivyd, Inc. (IVVD) appoints Michael Mina, M.D., Ph.D., distinguished physician and scientist, as Chief Medical Officer. Appointing a prominent physician-scientist as CMO represents a major strategic leadership enhancement for clinical and regulatory advancement.
24 Feb
New publication demonstrates variant-agnostic correlate of protection from COVID-19 for Invivyd's monoclonal antibody, enhancing understanding and confidence in COVID-19 antibodies. Variant-agnostic protection data significantly bolsters Invivyd's competitive positioning and investor sentiment for its COVID-19 antibody.
3 Feb
Invivyd, Inc. has aligned with the U.S. FDA to initiate the LIBERTY Phase 3 trial, which will evaluate the safety of its VYD2311 antibody compared to mRNA COVID vaccines. The trial aims to assess both the safety and immunological responses of co-administering the antibody with the vaccine. The alignment with the FDA on a Phase 3 trial represents a significant strategic move that could impact Invivyd's product offerings and market position.
24 Jan
Recent price target resets for Invivyd, Inc. (IVVD) have prompted analysts to reevaluate the company's growth potential and market position. These adjustments reflect changing perceptions about the company's pipeline and overall strategy, indicating a more optimistic outlook among investors. As a result, the stock's performance may be influenced by these revised targets, which could lead to increased investor interest and market activity. Price target resets indicate significant shifts in analyst sentiment that could impact investor behavior and stock performance.
22 Jan
Invivyd, Inc. has partnered with world champion skier Lindsey Vonn to promote awareness about antibodies and disease prevention among Americans. The collaboration aims to educate the public on the importance of antibodies in health and disease management, leveraging Vonn's influence to reach a broader audience. The partnership may enhance brand visibility and public engagement, potentially influencing market sentiment and product interest.
20 Jan
Invivyd, Inc. and the SPEAR Study Group have announced plans to initiate a Phase 2 study of VYD2311, targeting treatment for individuals suffering from Long COVID and those injured by COVID vaccines. The study is set to commence in mid-2026, aiming to address ongoing health issues related to the pandemic. The Phase 2 study represents a significant strategic move that could enhance Invivyd's product offerings and market position in the evolving landscape of post-COVID treatments.
14 Jan
Invivyd, Inc. (IVVD) reported strong growth in Q4, highlighting a significant increase in revenue and advancements in its COVID-19 antibody treatment, which has now progressed to Phase 3 clinical trials. The company aims to enhance its position in the market with this development, potentially addressing ongoing public health needs. Advancing the COVID antibody to Phase 3 is a major strategic move that could significantly alter the company's trajectory and investor sentiment.
Invivyd, Inc. (IVVD), a biotech firm specializing in monoclonal antibodies for infectious diseases like COVID-19, exemplifies the post-pandemic market’s extremes. Born from Adagio Therapeutics via a 2022 SPAC merger, its shares soared 1,300% in 2021 on treatment hype before crashing amid regulatory setbacks, including a 2023 FDA hold, leading to massive dilution and losses. Now trading near multi-year lows despite a pivotal shift—2024 revenue of $25.4 million from pemgarda, the first approved COVID pre-exposure prophylaxis antibody—the stock hints at undervaluation with elite 93.6% gross margins and a sub-1 price-to-book ratio.
The revenue inflection is compelling: analysts project 104% growth to $51.7 million in 2025, ballooning to $160 million by 2027, fueling a path to positive free cash flow by 2026 and narrowing losses. Insider activity mixes caution (executive sells) with optimism (a director’s $125k buy), while Wall Street’s consensus price target signals 540% upside, driven by pemgarda’s niche in immunocompromised prophylaxis amid variant pressures.
Yet biotech risks loom—ongoing dilution to 282 million shares, COVID market volatility, and execution hurdles—echoing historical swings seen in antibody plays. With efficiency from a lean 100-employee team and improving metrics decoupling from past lows, IVVD stands at a potential rebound crossroads, warranting close scrutiny for investors eyeing undervalued growth.